10-Q · May 14, 2026
cbdMD, Inc. reported an increase in revenues to $5.64 million for Q2 2026, a year-over-year growth of 19%, while gross profit margins decreased to 57.7%. The company experienced a reduced net loss for the quarter of…
Earnings analysis · 10-Q
YCBD earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The supplied filing text does not include the current-period income statement, balance sheet, cash-flow statement, segment data or MD&A results, so revenue, margins, EPS and free cash flow cannot be reported reliably…
Read full summary
The supplied filing text does not include the current-period income statement, balance sheet, cash-flow statement, segment data or MD&A results, so revenue, margins, EPS and free cash flow cannot be reported reliably here. The filing does document $61,990 of gross proceeds from issuing 100,000 ELOC shares, supporting liquidity but increasing dilution risk. Management reported effective disclosure controls, no material internal-control changes and no material pending litigation; risk factors were unchanged from the 2025 10-K.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
ELOC Provides $61,990 of Financing
The company issued 100,000 common shares under its ELOC for gross proceeds of $61,990, providing additional financing during the quarter.
-
Disclosure Controls Deemed Effective
Management concluded that disclosure controls and procedures were effective as of the end of the reporting period, with reasonable assurance over required reporting and communication.
-
No Material Control Changes
The company reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the most recent fiscal quarter.
-
No Material Pending Litigation
Management stated that it was not a party to any pending legal proceedings expected to have a material adverse effect on the business, financial condition, or results of operations.
What to watch
-
Ongoing Equity Financing and Dilution
The issuance of 100,000 common shares for $61,990 under the ELOC creates additional equity dilution and indicates continued reliance on capital-market financing.
-
Existing 2025 10-K Risks Remain
The filing states that there have been no material changes from the risk factors in the 2025 10-K, so the existing risks—including liquidity, accumulated losses, regulatory pressures and operating losses—remain applicable.
-
Potential Ordinary-Course Legal Exposure
Although no material legal proceedings were identified, the company disclosed that it may become involved in ordinary-course legal proceedings and referred investors to Note 10 for commitments and contingencies.
Management's outlook
No quantitative outlook or forward guidance is included in the supplied filing text; outlook appears deferred to the earnings press release or call.
Earlier filings 4
10-Q · February 17, 2026
cbdMD reported Q1 (period ended Dec 31, 2025) net sales of $5,016,904 and GAAP loss per share of $(0.04). Liquidity improved materially with cash of $3,387,933 (up $1,126,691 QoQ) following preferred stock proceeds of…
10-K · December 19, 2025
cbdMD's FY2025 10-K describes a business stabilizing revenues while cutting GAAP operating losses (from $3.3M in FY2024 to $2.1M in FY2025) and simplifying its capital structure through conversion of preferred stock.…
10-Q · August 14, 2025
cbdMD reported Q3 net sales of $4,606,796, down from $5,173,878 a year earlier, with gross margin of 61.5% and a wider loss from operations of $(904,686). Reported GAAP loss per share improved to $(0.21) (basic and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.